|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006826,
umls-concept:C0030705,
umls-concept:C0201734,
umls-concept:C0205179,
umls-concept:C0205390,
umls-concept:C0215136,
umls-concept:C0243071,
umls-concept:C0332174,
umls-concept:C0796479,
umls-concept:C1442162,
umls-concept:C1550718
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2002-9-16
|
|
pubmed:abstractText |
The study was designed to establish the maximum administered dose and maximum tolerated dose (MTD) of BMS-184476, an analogue of paclitaxel, given weekly for 3 consecutive weeks every 28 days, later amended to a regimen of weekly administration for 2 consecutive weeks every 21 days.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2788-97
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12231518-Adult,
pubmed-meshheading:12231518-Aged,
pubmed-meshheading:12231518-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:12231518-Diarrhea,
pubmed-meshheading:12231518-Dose-Response Relationship, Drug,
pubmed-meshheading:12231518-Drug Administration Schedule,
pubmed-meshheading:12231518-Female,
pubmed-meshheading:12231518-Humans,
pubmed-meshheading:12231518-Male,
pubmed-meshheading:12231518-Middle Aged,
pubmed-meshheading:12231518-Molecular Structure,
pubmed-meshheading:12231518-Neoplasms,
pubmed-meshheading:12231518-Neutropenia,
pubmed-meshheading:12231518-Paclitaxel,
pubmed-meshheading:12231518-Remission Induction,
pubmed-meshheading:12231518-Taxoids
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.
|
|
pubmed:affiliation |
Northern Centre for Cancer Treatment, Newcastle Upon Tyne, United Kingdom NE4 6BE.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
